Abstract:The nature of the proarrhythmic reactions induced by antiarrhythmic drugs is linked to the electrophysiologic effects of these agents. Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents. Its precise electrophysiologic mechanism is not fully elucidated, although the arrhythmia is generally considered to be due either to early afterdepolarization in the context of prolonged cardiac repolarization or to an increase in spatial or temporal dispersion of repolarization. Among the class III drugs the proarrhythmic risk appears to be lowest for amiodarone, probably due to its complex electrophysiologic profile that may create significant myocardial electrical homogeneity. In the case of d,l-sotalol, the incidence of torsades de pointes increases with dose and the baseline values of the QT interval. Where d-sotalol and other pure class III agents might fall into the varying spectrum of proarrhythmic potential remains unclear. That d-sotalol has been found to increase mortality in postinfarction patients with ventricular dysfunction (the Survival With Oral d-Sotalol [SWORD] trial) is a matter of considerable concern. It raises the possibility that such a phenomenon may be a common property of most, if not all, pure class III compounds. Accordingly, care must be taken to minimize the likelihood of proarrhythmia; in particular, therapy with a class III agent should only be initiated in the presence of a defined indication established on the basis of clinical trials. When class III antiarrhythmic drug-induced proarrhythmia occurs, immediate cessation of therapy with the responsible agent and correction of predisposing factors, such as electrolyte disorders or bradycardia, is mandatory. Intravenous administration of high-dose magnesium sulfate has been demonstrated to be effective in terminating and preventing new episodes of torsades de pointes. Temporary pacing may be necessary.

Ibutilide-induced arrhythmias: prevention and treatment

The effects of amiodarone on QT dispersion in patients with atrial fibrillation

[Efficacy and Safety of Ibutilide for Conversion of Atrial Fibrillation/flutter].

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management

T wave sensing test during ICD implantation procedure in inherited arrhythmias patients

Class III Antiarrhythmics and Periprocedural Torsades de Pointes

Prevention of Torsade de Pointes in Hospital Settings

Safety of Ibutilide in Converting Atrial Arrhythmia

Drug-induced QT interval prolongation and torsades de pointes

Effects of Ibutilide on Canine Cardiac Pacing Threshold and on Induction Rates of Atrial Fibrillation

Analysis on the Adverse Drug Reactions of Ibutilide Fumarate in the Treatment of Arrhythmia

Diagnosis and Treatment of Drug Induced Acquired Long QT Syndrome

QT Prolongation Preceding Ventricular Fibrillation After Amiodarone Administration: A Case Report

Dobutamine Infusion for Unmasking Long QT Syndrome and Torsades De Pointes.

Cardiac electrophysiologic effects of intravenous ibutilide compared with intravenous propafenone in patients with rencent-onset atrial fibrilation

Fluoroquinolone-induced torsade de pointes

Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review

Drug-induced increase in dispersion of ventricular repolarization in patients with heart failure with preserved ejection fraction

Drug-induced proarrhythmia: Discussion and considerations for clinical practice

Torsade de pointes caused by citalopram during the pacemaker battery-depletion phase: A case report